GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » European Biotech Acquisition Corp (NAS:EBACU) » Definitions » Change In Receivables

EBACU (European Biotech Acquisition) Change In Receivables : $0.00 Mil (TTM As of Dec. 2022)


View and export this data going back to 2021. Start your Free Trial

What is European Biotech Acquisition Change In Receivables?

European Biotech Acquisition's change in receivables for the quarter that ended in Dec. 2022 was $0.00 Mil. It means European Biotech Acquisition's Accounts Receivable stayed the same from Sep. 2022 to Dec. 2022 .

European Biotech Acquisition's change in receivables for the fiscal year that ended in Dec. 2022 was $0.00 Mil. It means European Biotech Acquisition's Accounts Receivable stayed the same from Dec. 2021 to Dec. 2022 .

European Biotech Acquisition's Accounts Receivable for the quarter that ended in Dec. 2022 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. European Biotech Acquisition's liquidation value for the three months ended in Dec. 2022 was $-8.24 Mil.

European Biotech Acquisition Change In Receivables Historical Data

The historical data trend for European Biotech Acquisition's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

European Biotech Acquisition Change In Receivables Chart

European Biotech Acquisition Annual Data
Trend Dec21 Dec22
Change In Receivables
- -

European Biotech Acquisition Quarterly Data
Jan21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Change In Receivables Get a 7-Day Free Trial - - - - -

European Biotech Acquisition Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

European Biotech Acquisition  (NAS:EBACU) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

European Biotech Acquisition's Days Sales Outstanding for the quarter that ended in Dec. 2022 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0/0*91
=

2. In Ben Graham's calculation of liquidation value, European Biotech Acquisition's accounts receivable are only considered to be worth 75% of book value:

European Biotech Acquisition's liquidation value for the quarter that ended in Dec. 2022 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=0.308-8.548+0.75 * 0+0.5 * 0
=-8.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

European Biotech Acquisition Change In Receivables Related Terms

Thank you for viewing the detailed overview of European Biotech Acquisition's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

European Biotech Acquisition Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » European Biotech Acquisition Corp (NAS:EBACU) » Definitions » Change In Receivables
Comparable Companies
CNTQ LION MEOA SCMA LATG NBST CCTS FRBN NMMC DMAQ GSHN PSTH XAMS:EPIC ASZ CCYC CVII KAHC DWAC IPOF PBAJ
Traded in Other Exchanges
N/A
Address
EPFL Innovation Park Building, Lausanne, CHE, 1015
Website
https://www.lspvc.com
European Biotech Acquisition Corp is a blank check company.
Executives
Mohammad Sohail Fazeli director JOHANNES VERMEERPLEIN 9, AMSTERDAM P7 1071 DV
Martijn Kleijwegt director JOHANNES VERMEERPLEIN 9, AMSTERDAM P7 1071 DV
Volkert H. Doeksen director RIOUWSTRAAT 10, THE HAGVE P7 2585HA
Fernandez De Araoz Eduardo Bravo officer: Chief Executive Officer JOHANNES VERMEERPLEIN 9, AMSTERDAM P7 1071 DV
Koen Sintnicolaas officer: Chief Financial Officer JOHANNES VERMEERPLEIN 9, AMSTERDAM P7 1071 DV
Lsp Sponsor Ebac B.v. 10 percent owner JOHANNES VERMEERPLEIN 9, AMSTERDAM P7 1071 DV
Van De Stolpe Onno director JOHANNES VERMEERPLEIN 9, AMSTERDAM, P7 1071 DV
Marcus Antonius Wegter director JOHANNES VERMEERPLEIN 9, AMSTERDAM P7 1071 DV
Lsp Management Group B.v. 10 percent owner JOHANNES VERMEERPLEIN 9, AMSTERDAM P7 1071 DV